Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 9
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Previously-Treated MSI-H/dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
Enrolment: 200 · Results not recorded
A Phase 2 Study of INCMGA00012 (Retifanlimab) in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Metastatic Merkel Cell Carcinoma
Enrolment: 107 · Results not recorded
Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
Esophageal Neoplasms · Esophageal Diseases
Enrolment: 21 · Results not recorded
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory CLL and Other Low Grade B Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Richter Syndrome
Enrolment: 65 · Results not recorded
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers (with anti-PD-1 antibody)
Breast Cancer · Head and Neck Cancer · Lymphoma · Pancreatic Cancer · Lung Cancer · Sarcoma
Enrolment: 111 · Results not recorded
A Phase I Study of Anetumab Ravtansine in Combination With Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies, or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Enrolment: 74 · Results not recorded
Pyroptosis-inducible Newcastle Disease Oncolytic Virus (PIN) Plus Sintilimab (Anti-PD1 Antibody) for Advanced pMMR/MSS Colorectal Cancer With Hepatic Metastases
Colorectal Cancer
Enrolment: 25 · Results not recorded
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Advanced Solid Tumors and Lymphomas
Tumor, Solid · Lymphoma, Non-Hodgkin · Triple Negative Breast Cancer
Enrolment: 168 · Results not recorded
Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With Pegylated Interferon Alfa-2b in Patients With Advanced-Stage Hepatocellular Carcinoma
Hepatocellular Carcinoma
Enrolment: 15 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryUnspecifiedRjOrl:SWISS and BALB/cJIntraperitoneal injection
Model: Spinal cord injury induced immune depression syndrome followed by methicillin susceptible Staphylococcus aureus pneumonia
Blockade of PD-1 improved survival of spinal cord injured, infected mice and enhanced interferon gamma production by natural killer T cells as well as the number of viable CD4 T cells.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
